Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Bevacizumab in Recurrent Glioblastoma
NCT05540275Phase 2Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in glioblastoma (GBM), sponsored by Henan Provincial People's Hospital. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05540275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540275.